JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Ventyx Biosciences Inc

Closed

2.64 -5.38

Overview

Share price change

24h

Current

Min

2.63

Max

2.84

Key metrics

By Trading Economics

Income

1.9M

-27M

Employees

81

EBITDA

2.4M

-30M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+331.82% upside

Dividends

By Dow Jones

Next Earnings

13 Aug 2025

Market Stats

By TradingEconomics

Market Cap

90M

194M

Previous open

8.02

Previous close

2.64

Ventyx Biosciences Inc Chart

Past performance is not a reliable indicator of future results.

Related News

23 Sept 2024, 12:43 UTC

Major Market Movers

Ventyx Biosciences Shares Rise Premarket on Sanofi Investment

Peer Comparison

Price change

Ventyx Biosciences Inc Forecast

Price Target

By TipRanks

331.82% upside

12 Months Forecast

Average 11.4 USD  331.82%

High 21 USD

Low 2 USD

Based on 8 Wall Street analysts offering 12 month price targets forVentyx Biosciences Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

5

Buy

3

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.